1 An Interventional Efficacy And Safety, Phase 2/3 Double-Blind, 2-Arm Study To Investigate Orally Administered PF-07321332/Ritonavir Compared With Placebo In Non-hospitalized Symptomatic Adult Participants With Covid-19 Who Are At Increased Risk Of Progressing To Severe Illness 2 AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLEBLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT LOW RISK OF PROGRESSING TO SEVERE ILLNESS 3 A PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 2 REGIMENS OF ORALLY ADMINISTERED PF 07321332/RITONAVIR IN PREVENTING SYMPTOMATIC SARS-COV-2 INFECTION IN ADULT HOUSEHOLD CONTACTS OF AN INDIVIDUAL WITH SYMPTOMATIC COVID-19 4 A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19 5 A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734 TM) in Participants with Moderate COVID-19 Compared to Standard of Care Treatment. 6 A Phase 3 Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734 TM) in Participants with Severe COVID-19. 7 A PHASE 3, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF A CLOSTRIDIUM DIFFICILE VACCINE IN ADULTS 50 YEARS OF AGE AND OLDER 8 A Prospective, Randomized, Open-Label, Comparative Study to Assess the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI) and Best Available Therapy for the Treatment of Serious Infections Due to Multi-Drug Resistant Gram Negative Bacteria Producing Metallo-β-Lactamase (MBL) 9 A Phase 3 Prospective, Randomized, Multicenter, Open Label, Central Assessor Blinded, Parallel Group, Comparative Study To Determine The Efficacy, Safety And Tolerability Of Aztreonam-Avibactam (ATM-AVI)±Metronidazole (MTZ) Versus Meropenem±Colistin (MER±COL) For The Treatment Of Serious Infections Due To Gram-Negative Bacteria, Including Metallo-β-Lactamase (MBL) – Producing Multidrug Resistant Pathogens, For Which There Are Limited Or No Treatment Options 10 A Clinical Performance Study Comparing Home Use COVID-19 Antigen Rapid Test and Molecular Diagnostics Test (RT-PCR) 1.Vstrip RV2 COVID-19 Antigen Rapid Test Home Use 11 VitaPCRTM SARS-CoV-2 assay kit clinical performance study 12 Clinical evaluation of SARS-CoV-2 nucleic acid point of care system testin 13 An ex vivo study to evaluate immune activation of BRM141 of peripheral blood mononuclear cells (PBMC) obtained from human immunodeficiency virus-1 (HIV-1) infected donors 14 VLA2001 COVID-19 Vaccine Expert Panel Member 15 MSD AP Molnupiravir Regional Subcommittee Member 16 Evaluation of the Safety and Efficacy of Silmitasertib (CX 4945) in Combination with Standard of Care (SOC) for Treating Patients with Community Acquired Pneumonia (CAP) Associated with SARS-CoV-2 and Influenza Viral Infections 17 A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA). 18 AN INTERVENTIONAL PHASE 2/3, ADAPTIVE, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE EFFICACY AND SAFETY OF ORAL SISUNATOVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULTS WITH RESPIRATORY SYNCYTIAL VIRUS INFECTION WHO ARE AT RISK OF PROGRESSION TO SEVERE ILLNESS 19 A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of EDP-938 in Non-hospitalized Adults with Acute Respiratory Syncytial Virus Infection who are at High Risk for Complications 20 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5245 for the Treatment of COVID-19 in Participants With High-Risk for Disease Progression 21　A Phase 3, Randomized, Observer‑blind, Active‑control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA‑1083 (SARS‑CoV‑2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age 22　A Phase 3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adults With COVID-19 at High Risk for Disease Progression 23　Evaluation of human interferon alpha administered oromucosally in the treatment of oral warts in HIV-seropositive subjects receiving combination anti-retroviral therapy 24　A PHASE III, RANDOMIZED, EVALUATOR-BLIND, TWO-STAGE, TWO-WAY CROSS-OVER, ACTIVE- AND PLACEBO-CONTROLLED, SIMULATION STUDY TO EVALUATE THE EFFECTIVENESS AND SAFETY OF EASY ANTISEPTIC CLOTH WITH 2% CHLORHEXIDINE GLUCONATE (AQUA) AS THE TOPICAL ANTISEPTICS IN HEALTHY VOLUNTEER

1 Principal investigator (AdimFlu-S influenza vaccine, MVC-COV1901, TetraVax-DV) 2 Co-investigator (CASTLE study, GSK1437173A, BMS-663068) 3 Early phase development (H5N1 vaccine, H7N9 vaccine, intranasal flu vaccine, SARS-CoV-2 subunit vaccine)

1. Adjunct Investigator, National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Taiwan 2. President, Infection Control Society of Taiwan 3. Chief, Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan 4. President, Infection Control Society of Taiwan 5. Vice-president, International Society for Human and Animal Mycology